Urapidil CAS 34661-75-1 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Urapidil CAS NO: 34661-75-1          

Synonyms:

6-[3-[4-(2-Methoxypheny/l)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione;

6-[[3-[4-(2-Methoxypheny/l)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil;

1,3-dimethyl-6-[[3-[4-(2-Methoxypheny/l)-1-piperazinyl]propyl]amino]-2,4(1H,3H)pyrimidine-dione;

Chemical & Physical Properties:

Appearance:Solid

Assay :≥99.0%

Density: 1.26 g/cm3

Boiling Point: 549℃ at 760 mmHg

Flash Point: 285.8℃

Refractive Index: 1.622

Vapor Pressure: 0.0±1.5 mmHg at 25℃

Safety Information:

Hazard Code: Xn

Risk Statements: R22-36/37/38

Safety Statement: S26

RTECS: YQ9862000

Toxicity: LD50 in male mice, rats (mg/kg): 750, 550 orally; 260, 145 i.v. (Koenig)

Urapidil is a sympatholytic antihypertensive drug. It acts as an α1-adrenoceptor antagonist and as an 5-HT1A receptor agonist Although an initial report suggested that urapidil was also an α2-adrenoceptor agonist, this was not substantiated in later studies that demonstrated it was devoid of agonist actions in the dog saphenous vein and the guinea-pig ileum. Unlike some other α1-adrenoceptor antagonists, urapidil does not elicit reflex tachycardia, and this may be related to its weak β1-adrenoceptor antagonist activity, as well as its effect on cardiac vagal drive. Urapidil is currently not approved by the U.S. Food and Drug Administration, but it is available in Europe.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.